Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
The anatomage table is one of the most advanced 3D real-tissue–based anatomy visualization systems in the world
Several technologies for hemoglobinopathies are being transferred to commercial partners
First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing
New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain
LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
Air Liquide will provide care for people living with respiratory diseases such as chronic obstructive pulmonary disease (COPD) and sleep apnea
Subscribe To Our Newsletter & Stay Updated
